Leyland‐Jones 2003.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 939, breast cancer (stage IV, M1); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 12‐14 g/dL planned ESA duration = 52 weeks
Outcomes	Primary: overall survival; secondary: Hb, transfusion, tumor control, QoL, time to progression
Notes	study number = 17100
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer‐generated
Allocation concealment?	Low risk	central randomization